Omeros (OMER) Competitors $6.03 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends OMER vs. VNDA, ESPR, RDUS, ANAB, CARA, PCRX, NKTR, ASMB, CPIX, and LLYShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Vanda Pharmaceuticals (VNDA), Esperion Therapeutics (ESPR), Radius Recycling (RDUS), AnaptysBio (ANAB), Cara Therapeutics (CARA), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). Omeros vs. Vanda Pharmaceuticals Esperion Therapeutics Radius Recycling AnaptysBio Cara Therapeutics Pacira BioSciences Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Omeros (NASDAQ:OMER) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations. Is OMER or VNDA more profitable? Omeros has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -8.59%. Omeros' return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -49.92% Vanda Pharmaceuticals -8.59%-3.02%-2.52% Do insiders & institutionals believe in OMER or VNDA? 48.8% of Omeros shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 12.3% of Omeros shares are held by insiders. Comparatively, 8.9% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer OMER or VNDA? Omeros currently has a consensus target price of $9.00, indicating a potential upside of 49.25%. Vanda Pharmaceuticals has a consensus target price of $15.50, indicating a potential upside of 216.33%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Omeros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor OMER or VNDA? In the previous week, Omeros had 13 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 16 mentions for Omeros and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.62 beat Omeros' score of 0.43 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 0 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vanda Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, OMER or VNDA? Vanda Pharmaceuticals has higher revenue and earnings than Omeros. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$117.81M-$2.31-2.61Vanda Pharmaceuticals$192.64M1.48$2.51M-$0.28-17.50 Which has more volatility and risk, OMER or VNDA? Omeros has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Does the MarketBeat Community believe in OMER or VNDA? Omeros received 206 more outperform votes than Vanda Pharmaceuticals when rated by MarketBeat users. Likewise, 71.10% of users gave Omeros an outperform vote while only 66.87% of users gave Vanda Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOmerosOutperform Votes74371.10% Underperform Votes30228.90% Vanda PharmaceuticalsOutperform Votes53766.87% Underperform Votes26633.13% SummaryOmeros and Vanda Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$349.44M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-2.614.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book-2.2710.126.936.25Net Income-$117.81M$153.61M$119.12M$225.93M7 Day Performance-13.24%-2.00%-1.83%-1.32%1 Month Performance47.07%-7.47%-3.64%0.60%1 Year Performance258.93%31.80%31.64%26.23% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros3.6817 of 5 stars$6.03flat$9.00+49.3%+244.6%$349.44MN/A-2.61198Analyst UpgradeVNDAVanda Pharmaceuticals4.4326 of 5 stars$4.90-0.4%$15.50+216.3%+36.9%$286.88M$192.64M-17.50203ESPREsperion Therapeutics3.9536 of 5 stars$2.41flat$8.17+238.9%+97.5%$474.86M$116.33M-3.77240Analyst ForecastRDUSRadius Recycling2.1412 of 5 stars$18.46+5.1%N/A-27.2%$492.65M$2.74B-1.973,011ANABAnaptysBio2.4863 of 5 stars$20.31+1.7%$54.64+169.0%+40.0%$607.66M$17.16M-3.34100CARACara Therapeutics3.9304 of 5 stars$0.31flat$2.32+660.7%-71.2%$16.51M$20.97M0.0055Analyst ForecastPCRXPacira BioSciences3.9929 of 5 stars$17.03+1.8%$23.50+38.0%-38.5%$772.48M$674.98M-8.39720Positive NewsNKTRNektar Therapeutics3.9416 of 5 stars$1.00-2.9%$3.50+250.0%+92.3%$189.99M$90.12M0.00220Gap UpASMBAssembly Biosciences4.1387 of 5 stars$15.02-2.1%$35.00+133.0%+86.5%$97.50M$7.16M0.00100CPIXCumberland Pharmaceuticals0.6596 of 5 stars$1.12+0.9%N/A-34.9%$15.59M$39.55M0.0080Analyst ForecastLLYEli Lilly and Company4.9913 of 5 stars$753.41+3.2%$1,007.94+33.8%+26.0%$692.74B$34.12B81.4543,000Analyst RevisionPositive News Related Companies and Tools Related Companies VNDA Alternatives ESPR Alternatives RDUS Alternatives ANAB Alternatives CARA Alternatives PCRX Alternatives NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OMER) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
